ProCE Banner Activity

Where Are We Now? A Decade of Using Newer β-lactams to Treat Pseudomonas aeruginosa With Difficult-to-Treat Resistance

Clinical Thought

Over the past decade, new agents targeting DTR P. aeruginosa have entered the scene, but where does that leave us? Read my commentary on how these agents fall into the treatment cascade, including my approach to treating these infections. 

Released: September 25, 2024

Expiration: September 24, 2025

Share

Faculty

Marguerite L. Monogue

Marguerite L. Monogue, PharmD, BCIDP

Infectious Diseases Pharmacy Specialist
Assistant Professor, Division of Internal Medicine
University of Texas Southwestern
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Shionogi Pharma, Inc.

Shionogi Pharma, Inc.

Disclosure

Primary Author

Marguerite L. Monogue, PharmD, BCIDP

Infectious Diseases Pharmacy Specialist
Assistant Professor, Division of Internal Medicine
University of Texas Southwestern
Dallas, Texas

Marguerite L. Monogue, PharmD, BCIDP: researcher: Shionogi.